Inhaled COVID Vaccine on the way
The AeroVax study, supported by $8 million in funding from the Canadian Institutes of Health Research (CIHR), will test needle-free vaccines developed to provide protection from SARS-CoV-2.
Led by researchers Fiona Smaill and Zhou Xing from the Michael G. DeGroote Institute for Infectious Disease Research (IIDR) at McMaster University, the multicentre trial will evaluate the new vaccine in a broad study group, while also confirming safety.
Findings from pre-clinical studies and soon-to-be-published data from the Phase 1 trial indicate that McMaster’s inhaled vaccine is more effective at inducing immune responses than traditional injected vaccines, because it directly targets the lungs and upper airways, where the virus first enters the body.
“While the current, needle-based COVID-19 vaccines have prevented a tremendous amount of death and hospitalization, they haven’t really changed a lot of people’s experience with getting recurrent infections,” says Smaill, a professor in the department of Pathology & Molecular Medicine.
“So we’re looking to change that by providing robust protection directly at the site of infection.”
The new vaccine is entirely Canadian, from design and biomanufacturing at McMaster’s Robert E. Fitzhenry Vector Laboratory to pre-clinical and clinical testing conducted by a team of Canadian experts, with Canadian participants, at Canadian research sites.
For the new trial, researchers hope to include 350 participants from across Canada at clinical trial sites in Hamilton, Ottawa and Halifax. Those eligible for participation must:
- Have at least three doses of an mRNA COVID-19 vaccine
- Have never received the AstraZeneca COVID-19 vaccine
- Have not had a COVID-19 infection or COVID-19 vaccination within three months prior to enrollment
- Have no diagnosis of lung disease
- Be available to attend trial visits in-person
- Be between 18 and 65 years of age.
The study is a randomized placebo-controlled trial, and two-thirds of participants will receive the vaccine, while the other third will receive a placebo, Smaill says.
Participants won’t know which group they belong to, but both groups are equally integral to the study.
“Clinical trials, like this one, are the only way to firmly establish the efficacy and safety of novel health products,” Smaill says.
Following the study, researchers will move the vaccine into phase-3 clinical trials which will test efficacy in a larger population group and ultimately position the vaccine for market approval.
Dr. Xing is the 2023 recipient of the Hardy Cinader Award, recognizing distinguished scientific leadership and accomplishments in the field of immunology.
University specialists apparently did not notice sudden deaths, myocarditis, turbo cancers, paralysation and other sides effects of Covide 19 “vaccine”, that is strongly reported from various independent sources and experts, as Dr. Wiliam Makis, Dr. Peter Mc Cullouough, Dr. Charles Hoffe and others.
Once inhaled vaccines are developed, they can be easily misused via air ventilation in shopping malls or public buildings, perhaps spread by planes, without people’s consent, and that is a serious problem.
DB
